Drug Trial Radar · NCT06642909
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Nov 13, 2024
Primary completion
Mar 31, 2027
Study completion May 10, 2027
Sponsor
- Lead sponsor
- BioRay Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, open label, cyclosporine controlled Phase II trial aimed at evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of Zuberitamab in patients with primary membranous nephropathy, and exploring the Phase III dosing regimen, sample size, and endpoint evaluation time
Conditions
- Primary Membranous Nephropathy
Interventions
Zuberitamab 600mgDrug
administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
Zuberitamab 1000mgDrug
administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
cyclosporineDrug
Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects who achieved overall response (OR) in the urinary protein/creatinine ratio (UPCR) at week 76Time frame: Week 76
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.